Parkinsonian DisordersInorganic ChemicalsSupranuclear Palsy, ProgressiveMultiple System AtrophyParkinson DiseaseMental DisordersBipolar DisorderMood DisordersAnxiety DisordersLevodopaParkinson Disease, SecondaryDiagnostic and Statistical Manual of Mental DisordersAntiparkinson Agents1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineDepressive Disorder, MajorDepressive DisorderBrainGlobus PallidusHypokinesiaMuscle RigidityBrain ChemistrySubstance-Related DisordersAttention Deficit Disorder with HyperactivityStress Disorders, Post-TraumaticSubthalamic NucleusObsessive-Compulsive DisorderPsychiatric Status Rating ScalesSchizophreniaPsychotic DisordersDyskinesia, Drug-InducedComorbidityBrain InjuriesBrain MappingDyskinesiasDeep Brain StimulationDopaminePhobic DisordersSubstantia NigraOxidopamineCorpus StriatumAutistic DisorderBrain NeoplasmsMovement DisordersTremorMagnetic Resonance ImagingExtrapyramidal TractsNeuronsChild Development Disorders, PervasiveSomatoform DisordersDopamine AgentsInterview, PsychologicalCognition DisordersConduct DisorderBasal GangliaDiagnosis, Dual (Psychiatry)CarbidopaDisease Models, AnimalPrevalenceBehavior, AnimalOlivopontocerebellar AtrophiesNeurotic DisordersPsychotropic DrugsAttention Deficit and Disruptive Behavior DisordersAnalysis of VarianceNeural PathwaysRisk FactorsBenserazideNeuropsychological TestsBasal Ganglia DiseasesSeverity of Illness IndexAlcoholismMazindolImpulse Control DisordersTime FactorsSleep DisordersPutamenBorderline Personality Disorder